0000950170-24-010477.txt : 20240202 0000950170-24-010477.hdr.sgml : 20240202 20240202160518 ACCESSION NUMBER: 0000950170-24-010477 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Evans John M. CENTRAL INDEX KEY: 0001786304 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 24591336 MAIL ADDRESS: STREET 1: C/O BEAM THERAPEUTICS INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-01-31 0001745999 Beam Therapeutics Inc. BEAM 0001786304 Evans John M. C/O BEAM THERAPEUTICS INC., 238 MAIN STREET CAMBRIDGE MA 02142 true true false false CEO true Common Stock 2024-01-31 4 S false 60000 25.33 D 1058262 D Common Stock 103000 I By John M. Evans, III 2018 Irrevocable Trust Stock Option (Right to Buy) 24.40 2024-01-31 4 A false 155000 24.40 A 2034-01-31 Common Stock 155000 155000 D These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $24.93 to $25.92 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 283 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023. This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. By: /s/ Christine Bellon, Attorney-in-fact 2024-02-02